News | Radiation Therapy | April 26, 2017

Nine New Disease Sites Added to the NCCN Radiation Therapy Compendium

Compendium provides a single access point for radiation therapy recommendations within 33 NCCN Guidelines

Nine New Disease Sites Added to the NCCN Radiation Therapy Compendium

April 26, 2017 — The National Comprehensive Cancer Network (NCCN) continues to build its NCCN Radiation Therapy Compendium with the publication of radiation therapy (RT) recommendations from an additional nine NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines):

The new guidelines include recommendations for:

  • Acute Lymphoblastic Leukemia, Version 2.2016;
  • Basal Cell Skin Cancer, Version 1.2017;
  • Dermatofibrosarcoma Protuberans, Version 1.2017;
  • Gastric Cancer, Version 1.2017;
  • Hodgkin Lymphoma, Version 1.2017;
  • Merkel Cell Carcinoma, Version 1.2017;
  • Ovarian Cancer, Version 1.2017;
  • Squamous Cell Skin Cancer, Version 1.2017; and
  • Thymomas and Thymic Carcinomas, Version 1.2017.

Launched in March 2017, the NCCN Radiation Therapy Compendium now includes recommendations from 33 NCCN Guidelines. Additional cancer types will be published on a rolling basis over the coming months.

The compendium provides guidance on all RT modalities recommended within the NCCN Guidelines, including:

  • Intensity modulated radiation therapy (IMRT);
  • Intra-operative radiation therapy (IORT);
  • Stereotactic radiosurgery (SRS)/stereotactic body radiotherapy (SBRT)/stereotactic ablative radiotherapy (SABR);
  • Image-guided radiotherapy (IGRT);
  • Low dose-rate brachytherapy (LDR)/High dose-rate brachytherapy (HDR);
  • Radioisotope; and
  • Particle therapy.

Transparency of NCCN Guidelines and Compendia development is central to the philosophy, policies and procedures of NCCN. NCCN posts the policies and processes for developing and maintaining the NCCN Guidelines. These policies are available to the public on the NCCN website. Identification of newly published research, NCCN Member Institution review, external stakeholder submissions and panel review occur on an ongoing basis with at least annual review performed for NCCN Guidelines for each disease.

For more information: www.nccn.org

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...